Fosun Pharma's new crown vaccine has been approved for emergency use in Hong Kong, China

(Shanghai, China and Mainz, Germany, 25 January 2021) Shanghai Fosun Pharma (Group) Co., Ltd. ("Fosun Pharma" or "Group", stock code: 600196. SH, 02196.HK) and BioNTech SE ("BioNTech" or "Company", NASDAQ Stock Code: BNTX) jointly announced that the new crown vaccine COMIRNATY® (i.e. BNT162b2,Chinese Commodity Name: BitaiTM) based on BioNTech's mRNA technology has been approved for emergency use in Hong Kong by the Food and Health Bureau of the Hong Kong Special Administrative Region.
future supply of vaccines to Hong Kong will be produced directly from BioNTech's plant in Germany for supply, distribution and application under the HKSAR Government's new crown vaccination programme.
we are heartened and encouraged by the recognition of the emergency use of the
" BitaiTM in Hong Kong, China, which is an important milestone in Fosun Pharma's and BioNTech's joint efforts to achieve wider global access to vaccines.
Fosun Pharma and BioNTech have been working closely together to actively promote clinical trials and registration of the mRNA new crown vaccine in the Greater China region," said Wu Yifang, Chairman and CEO of Fosun Pharma.
we will closely co-operate with the vaccination programme of the Hong Kong Special Administrative Region Government to ensure that Hong Kong people can be vaccinated against the new mRNA vaccine at an early age and to protect the health of thousands of households in Hong Kong.
" March 16, 2020, BioNTech and Fosun Pharma announced a strategic cooperation agreement to jointly develop and commercialize vaccine products for new coronavirus in Greater China based on BioNTech's proprietary mRNA technology platform.
BioNTech CEO and Co-Founder Uur Sahin M., M.D., said, "The recognition of emergency use in Hong Kong, China, marks a step closer to achieving the goal of global supply of the new crown vaccine and confirms our successful partnership with Fosun Pharma in the fight against the epidemic."
the future, we hope to complete the distribution of vaccines in Asia as soon as possible and will continue to test for potential virus variants.
" According to the results of phase III clinical trials worldwide, BioNTech's mRNA new crown vaccine has reached all major therapeutic endpoints, with a 95 percent effectiveness in preventing new coronavirus infections, more than 94 percent effective for adults over 65 years of age, and consistent effectiveness across all ages, genders, races, and ethnic groups.
, the vaccine has been licensed by health regulators in more than 50 countries and regions, including the United Kingdom, the United States, Canada and the European Union.
COMIRNATY ® is a new crown vaccine for mRNA (Messenger RNA).
mRNA is a naturally occurring molecule with a "blueprint" of human cells that produces target proteins or immunogens that activate the body's immune response against various pathogens.
the mRNA vaccine uses the genetic sequence of the virus rather than the virus itself, therefore, the mRNA vaccine has no viral components and no risk of infection.
At the same time, mRNA vaccines have a short development cycle and the ability to rapidly develop new candidate vaccines to respond to viral mutations;
all vaccines, including mRNA and traditional vaccines, are designed to prevent viral infections by activating the immune system to produce long-lasting antibodies and T-cell responses to SARS-CoV-2.
source: Fosun Pharma